Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic's Melody Transcatheter Pulmonary Valve Gets FDA Panel Date

This article was originally published in The Gray Sheet

Executive Summary

FDA's Circulatory System Devices Panel will review a humanitarian device exemption application for Medtronic's Melody transcatheter pulmonary valve and Ensemble delivery system July 22, according to a July 2 Federal Register notice

You may also be interested in...



Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys

Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion

Medtronic Melody Data Sings; Transcatheter Heart Valve Awaits HDE

Feasibility trial results show Medtronic's Melody transcatheter pulmonary heart valve reduces right ventricular volume by 18% in patients with dysfunctional right ventricular outflow tract conduits

‘Entirely New Theory Of Legal Liability’: FTC v. Amazon Is ‘Dark Patterns’ Case To Watch

Amazon’s motion to dismiss is pending in Washington State’s Western District in litigation concerning Prime subscriptions and alleged “dark patterns” used to trick consumers into enrolling and hinder cancellations, according to the US Federal Trade Commission. The case could be instructive for any and all digital marketers at a time of legal uncertainty surrounding the topic.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel